The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-10

AUTHORS

M. Calguneri, S. Apras, Z. Ozbalkan, I. Ertenli, S. Kiraz, M. A. Ozturk, I. Celik

ABSTRACT

Pharmacological treatment of diffuse systemic sclerosis (SSc) directed at the tissue fibrosis has generally been ineffective. Many immunosuppressive drugs have been tried as therapy for SSc, regardless of the disease subtype and/or stage. The aim of this study was to show the efficacy and the toxicity of oral cyclophosphamide and prednisolone therapy on the prevention of fibrosis-based tissue damage in the early stages of the diffuse SSc. Twenty-seven patients with early diffuse SSc were treated with oral cyclophosphamide (1–2 mg/kg/day) plus oral prednisolone (40 mg/every other day) between the years 1995 and 1998. The results regarding the efficacy and toxicity of cyclophosphamide were compared with those of 22 early SSc patients who had been treated with oral D-penicillamine between 1992 and 1995. All the patients were evaluated using clinical and laboratory parameters every 6 months for 2 years. There was a significant improvement on the skin score, maximal oral opening, flexion index, predicted forced vital capacity (FVC) and carbon monoxide diffusing capacity (DLCO) in the cyclophosphamide group. The decrease in skin score in the cyclophosphamide group started earlier than in the D-penicillamine group. No life-threatening or irreversible adverse reaction was observed. This open study supports the use of oral cyclophosphamide plus prednisolone therapy to prevent fibrosis and its complications in the early stages of diffuse SSc. More... »

PAGES

289-294

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10067-003-0733-2

DOI

http://dx.doi.org/10.1007/s10067-003-0733-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1041101930

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/14579158


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisolone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Probability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Scleroderma, Systemic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Statistics, Nonparametric", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hacettepe University School of Medicine, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Hacettepe University School of Medicine, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calguneri", 
        "givenName": "M.", 
        "id": "sg:person.01071137677.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071137677.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hacettepe University School of Medicine, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Hacettepe University School of Medicine, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Apras", 
        "givenName": "S.", 
        "id": "sg:person.01301012316.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301012316.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hacettepe University School of Medicine, Sehit Cetin Gorg\u00fc Sok, 17/3, TR-06570, Ankara, Maltepe, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Hacettepe University School of Medicine, Turkey", 
            "Hacettepe University School of Medicine, Sehit Cetin Gorg\u00fc Sok, 17/3, TR-06570, Ankara, Maltepe, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ozbalkan", 
        "givenName": "Z.", 
        "id": "sg:person.01102254177.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102254177.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hacettepe University School of Medicine, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Hacettepe University School of Medicine, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ertenli", 
        "givenName": "I.", 
        "id": "sg:person.01010746120.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010746120.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hacettepe University School of Medicine, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Hacettepe University School of Medicine, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kiraz", 
        "givenName": "S.", 
        "id": "sg:person.01171322744.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171322744.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hacettepe University School of Medicine, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Hacettepe University School of Medicine, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ozturk", 
        "givenName": "M. A.", 
        "id": "sg:person.011712636000.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011712636000.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hacettepe University School of Medicine, Turkey", 
          "id": "http://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Hacettepe University School of Medicine, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Celik", 
        "givenName": "I.", 
        "id": "sg:person.01355154512.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355154512.10"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2003-10", 
    "datePublishedReg": "2003-10-01", 
    "description": "Pharmacological treatment of diffuse systemic sclerosis (SSc) directed at the tissue fibrosis has generally been ineffective. Many immunosuppressive drugs have been tried as therapy for SSc, regardless of the disease subtype and/or stage. The aim of this study was to show the efficacy and the toxicity of oral cyclophosphamide and prednisolone therapy on the prevention of fibrosis-based tissue damage in the early stages of the diffuse SSc. Twenty-seven patients with early diffuse SSc were treated with oral cyclophosphamide (1\u20132 mg/kg/day) plus oral prednisolone (40 mg/every other day) between the years 1995 and 1998. The results regarding the efficacy and toxicity of cyclophosphamide were compared with those of 22 early SSc patients who had been treated with oral D-penicillamine between 1992 and 1995. All the patients were evaluated using clinical and laboratory parameters every 6 months for 2 years. There was a significant improvement on the skin score, maximal oral opening, flexion index, predicted forced vital capacity (FVC) and carbon monoxide diffusing capacity (DLCO) in the cyclophosphamide group. The decrease in skin score in the cyclophosphamide group started earlier than in the D-penicillamine group. No life-threatening or irreversible adverse reaction was observed. This open study supports the use of oral cyclophosphamide plus prednisolone therapy to prevent fibrosis and its complications in the early stages of diffuse SSc.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10067-003-0733-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1093299", 
        "issn": [
          "0770-3198", 
          "1434-9949"
        ], 
        "name": "Clinical Rheumatology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4-5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "keywords": [
      "diffuse systemic sclerosis", 
      "early diffuse systemic sclerosis", 
      "systemic sclerosis", 
      "oral cyclophosphamide", 
      "prednisolone therapy", 
      "cyclophosphamide group", 
      "skin score", 
      "carbon monoxide diffusing capacity", 
      "early SSc patients", 
      "maximal oral opening", 
      "toxicity of cyclophosphamide", 
      "oral prednisolone", 
      "open study", 
      "laboratory parameters", 
      "SSc patients", 
      "penicillamine group", 
      "immunosuppressive drugs", 
      "vital capacity", 
      "pharmacological treatment", 
      "adverse reactions", 
      "cyclophosphamide", 
      "diffusing capacity", 
      "disease subtypes", 
      "tissue fibrosis", 
      "tissue damage", 
      "patients", 
      "therapy", 
      "flexion index", 
      "early stages", 
      "prednisolone", 
      "sclerosis", 
      "efficacy", 
      "fibrosis", 
      "oral opening", 
      "significant improvement", 
      "scores", 
      "group", 
      "toxicity", 
      "complications", 
      "years 1995", 
      "subtypes", 
      "prevention", 
      "months", 
      "drugs", 
      "penicillamine", 
      "treatment", 
      "study", 
      "stage", 
      "aim", 
      "years", 
      "damage", 
      "index", 
      "decrease", 
      "improvement", 
      "capacity", 
      "use", 
      "opening", 
      "results", 
      "reaction", 
      "parameters", 
      "fibrosis-based tissue damage", 
      "monoxide diffusing capacity", 
      "irreversible adverse reaction"
    ], 
    "name": "The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis", 
    "pagination": "289-294", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1041101930"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10067-003-0733-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "14579158"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10067-003-0733-2", 
      "https://app.dimensions.ai/details/publication/pub.1041101930"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_376.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10067-003-0733-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10067-003-0733-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10067-003-0733-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10067-003-0733-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10067-003-0733-2'


 

This table displays all metadata directly associated to this object as RDF triples.

249 TRIPLES      21 PREDICATES      110 URIs      102 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10067-003-0733-2 schema:about N04fbe15759ef4015bf8cc8ddeeb8d45b
2 N081272ed4c94473c8ff84a145a0ec323
3 N17627bd673884620a59546334416b5af
4 N2e525f09621f4736b3f6df5eedca67d9
5 N2e81a4341df345b4b2370b56b12a0cbb
6 N3535255e76ef4f3fa4b14853765879ae
7 N3d20519ad0954228953e5d743a42ffa0
8 N4c951fababaf4532b4f77ef1ccbce17b
9 N50bdf72108694ae7b30c4d04d6226381
10 N5263a2cd26d34a07adb495203a345c2f
11 N5e5fc38a35f04dd690bf8a73649c7499
12 N717c105f660c4df783da23f6e5ecc2e0
13 N83e409f18a4742e9a7c05bf1cd366820
14 Na13600e757c44b81ba510b4a15a8230c
15 Na82494b89a6b472eade34ac99533dd58
16 Nace493fbc4d64fcf84bd6eb34f98aa6b
17 Nafd94ed856d7499cb80cb22c9c838e43
18 Nc2bd1a542d00497e804ea43b05c2adb8
19 Nc33db36a60884c2eacea0063f1a075f6
20 Nd72f809a55254f13afa57ebd12da6eb7
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author Na599e7a4515d40ad9debad4b4655c4b6
24 schema:datePublished 2003-10
25 schema:datePublishedReg 2003-10-01
26 schema:description Pharmacological treatment of diffuse systemic sclerosis (SSc) directed at the tissue fibrosis has generally been ineffective. Many immunosuppressive drugs have been tried as therapy for SSc, regardless of the disease subtype and/or stage. The aim of this study was to show the efficacy and the toxicity of oral cyclophosphamide and prednisolone therapy on the prevention of fibrosis-based tissue damage in the early stages of the diffuse SSc. Twenty-seven patients with early diffuse SSc were treated with oral cyclophosphamide (1–2 mg/kg/day) plus oral prednisolone (40 mg/every other day) between the years 1995 and 1998. The results regarding the efficacy and toxicity of cyclophosphamide were compared with those of 22 early SSc patients who had been treated with oral D-penicillamine between 1992 and 1995. All the patients were evaluated using clinical and laboratory parameters every 6 months for 2 years. There was a significant improvement on the skin score, maximal oral opening, flexion index, predicted forced vital capacity (FVC) and carbon monoxide diffusing capacity (DLCO) in the cyclophosphamide group. The decrease in skin score in the cyclophosphamide group started earlier than in the D-penicillamine group. No life-threatening or irreversible adverse reaction was observed. This open study supports the use of oral cyclophosphamide plus prednisolone therapy to prevent fibrosis and its complications in the early stages of diffuse SSc.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree false
30 schema:isPartOf N06517957952f4fdbaf8e35b2b6c0be9c
31 N4b2f996fde654e75b8dec7a0a0a514f9
32 sg:journal.1093299
33 schema:keywords SSc patients
34 adverse reactions
35 aim
36 capacity
37 carbon monoxide diffusing capacity
38 complications
39 cyclophosphamide
40 cyclophosphamide group
41 damage
42 decrease
43 diffuse systemic sclerosis
44 diffusing capacity
45 disease subtypes
46 drugs
47 early SSc patients
48 early diffuse systemic sclerosis
49 early stages
50 efficacy
51 fibrosis
52 fibrosis-based tissue damage
53 flexion index
54 group
55 immunosuppressive drugs
56 improvement
57 index
58 irreversible adverse reaction
59 laboratory parameters
60 maximal oral opening
61 monoxide diffusing capacity
62 months
63 open study
64 opening
65 oral cyclophosphamide
66 oral opening
67 oral prednisolone
68 parameters
69 patients
70 penicillamine
71 penicillamine group
72 pharmacological treatment
73 prednisolone
74 prednisolone therapy
75 prevention
76 reaction
77 results
78 sclerosis
79 scores
80 significant improvement
81 skin score
82 stage
83 study
84 subtypes
85 systemic sclerosis
86 therapy
87 tissue damage
88 tissue fibrosis
89 toxicity
90 toxicity of cyclophosphamide
91 treatment
92 use
93 vital capacity
94 years
95 years 1995
96 schema:name The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis
97 schema:pagination 289-294
98 schema:productId N5dcd3327e0a34e6ca961037e864ae636
99 N6c40a61670be4d178a8d86516cf6e40a
100 Nba3f641651f6484ca41406a94155a643
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041101930
102 https://doi.org/10.1007/s10067-003-0733-2
103 schema:sdDatePublished 2021-11-01T18:06
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N7dd3f0f826204277a82aeabfb195e7fe
106 schema:url https://doi.org/10.1007/s10067-003-0733-2
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N04fbe15759ef4015bf8cc8ddeeb8d45b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Prospective Studies
112 rdf:type schema:DefinedTerm
113 N06517957952f4fdbaf8e35b2b6c0be9c schema:volumeNumber 22
114 rdf:type schema:PublicationVolume
115 N081272ed4c94473c8ff84a145a0ec323 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Prednisolone
117 rdf:type schema:DefinedTerm
118 N17627bd673884620a59546334416b5af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Scleroderma, Systemic
120 rdf:type schema:DefinedTerm
121 N2e525f09621f4736b3f6df5eedca67d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Male
123 rdf:type schema:DefinedTerm
124 N2e81a4341df345b4b2370b56b12a0cbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Adult
126 rdf:type schema:DefinedTerm
127 N3535255e76ef4f3fa4b14853765879ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Treatment Outcome
129 rdf:type schema:DefinedTerm
130 N3d20519ad0954228953e5d743a42ffa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Probability
132 rdf:type schema:DefinedTerm
133 N3f32be07ce8549e997260aa98f6ed991 rdf:first sg:person.01171322744.01
134 rdf:rest N9b60d9e9877b46c2a996234db9b782ee
135 N4b2f996fde654e75b8dec7a0a0a514f9 schema:issueNumber 4-5
136 rdf:type schema:PublicationIssue
137 N4c951fababaf4532b4f77ef1ccbce17b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Drug Administration Schedule
139 rdf:type schema:DefinedTerm
140 N50bdf72108694ae7b30c4d04d6226381 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Follow-Up Studies
142 rdf:type schema:DefinedTerm
143 N5263a2cd26d34a07adb495203a345c2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Statistics, Nonparametric
145 rdf:type schema:DefinedTerm
146 N5dafb9c77aa74b708349d6e2545909fc rdf:first sg:person.01301012316.26
147 rdf:rest N7077068427314e7aab564a3fcfdaa4a3
148 N5dcd3327e0a34e6ca961037e864ae636 schema:name dimensions_id
149 schema:value pub.1041101930
150 rdf:type schema:PropertyValue
151 N5e5fc38a35f04dd690bf8a73649c7499 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Risk Assessment
153 rdf:type schema:DefinedTerm
154 N6c40a61670be4d178a8d86516cf6e40a schema:name pubmed_id
155 schema:value 14579158
156 rdf:type schema:PropertyValue
157 N7077068427314e7aab564a3fcfdaa4a3 rdf:first sg:person.01102254177.19
158 rdf:rest Nb32cae61f27b431683bf941d13481c53
159 N717c105f660c4df783da23f6e5ecc2e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Cohort Studies
161 rdf:type schema:DefinedTerm
162 N7333c187dfc74bf49788c5f4167a1d01 rdf:first sg:person.01355154512.10
163 rdf:rest rdf:nil
164 N7dd3f0f826204277a82aeabfb195e7fe schema:name Springer Nature - SN SciGraph project
165 rdf:type schema:Organization
166 N83e409f18a4742e9a7c05bf1cd366820 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Administration, Oral
168 rdf:type schema:DefinedTerm
169 N9b60d9e9877b46c2a996234db9b782ee rdf:first sg:person.011712636000.38
170 rdf:rest N7333c187dfc74bf49788c5f4167a1d01
171 Na13600e757c44b81ba510b4a15a8230c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Middle Aged
173 rdf:type schema:DefinedTerm
174 Na599e7a4515d40ad9debad4b4655c4b6 rdf:first sg:person.01071137677.71
175 rdf:rest N5dafb9c77aa74b708349d6e2545909fc
176 Na82494b89a6b472eade34ac99533dd58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Cyclophosphamide
178 rdf:type schema:DefinedTerm
179 Nace493fbc4d64fcf84bd6eb34f98aa6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Dose-Response Relationship, Drug
181 rdf:type schema:DefinedTerm
182 Nafd94ed856d7499cb80cb22c9c838e43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Humans
184 rdf:type schema:DefinedTerm
185 Nb32cae61f27b431683bf941d13481c53 rdf:first sg:person.01010746120.06
186 rdf:rest N3f32be07ce8549e997260aa98f6ed991
187 Nba3f641651f6484ca41406a94155a643 schema:name doi
188 schema:value 10.1007/s10067-003-0733-2
189 rdf:type schema:PropertyValue
190 Nc2bd1a542d00497e804ea43b05c2adb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Female
192 rdf:type schema:DefinedTerm
193 Nc33db36a60884c2eacea0063f1a075f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Drug Therapy, Combination
195 rdf:type schema:DefinedTerm
196 Nd72f809a55254f13afa57ebd12da6eb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Severity of Illness Index
198 rdf:type schema:DefinedTerm
199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
200 schema:name Medical and Health Sciences
201 rdf:type schema:DefinedTerm
202 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
203 schema:name Clinical Sciences
204 rdf:type schema:DefinedTerm
205 sg:journal.1093299 schema:issn 0770-3198
206 1434-9949
207 schema:name Clinical Rheumatology
208 schema:publisher Springer Nature
209 rdf:type schema:Periodical
210 sg:person.01010746120.06 schema:affiliation grid-institutes:grid.14442.37
211 schema:familyName Ertenli
212 schema:givenName I.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010746120.06
214 rdf:type schema:Person
215 sg:person.01071137677.71 schema:affiliation grid-institutes:grid.14442.37
216 schema:familyName Calguneri
217 schema:givenName M.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071137677.71
219 rdf:type schema:Person
220 sg:person.01102254177.19 schema:affiliation grid-institutes:grid.14442.37
221 schema:familyName Ozbalkan
222 schema:givenName Z.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102254177.19
224 rdf:type schema:Person
225 sg:person.011712636000.38 schema:affiliation grid-institutes:grid.14442.37
226 schema:familyName Ozturk
227 schema:givenName M. A.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011712636000.38
229 rdf:type schema:Person
230 sg:person.01171322744.01 schema:affiliation grid-institutes:grid.14442.37
231 schema:familyName Kiraz
232 schema:givenName S.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171322744.01
234 rdf:type schema:Person
235 sg:person.01301012316.26 schema:affiliation grid-institutes:grid.14442.37
236 schema:familyName Apras
237 schema:givenName S.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301012316.26
239 rdf:type schema:Person
240 sg:person.01355154512.10 schema:affiliation grid-institutes:grid.14442.37
241 schema:familyName Celik
242 schema:givenName I.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355154512.10
244 rdf:type schema:Person
245 grid-institutes:grid.14442.37 schema:alternateName Hacettepe University School of Medicine, Sehit Cetin Gorgü Sok, 17/3, TR-06570, Ankara, Maltepe, Turkey
246 Hacettepe University School of Medicine, Turkey
247 schema:name Hacettepe University School of Medicine, Sehit Cetin Gorgü Sok, 17/3, TR-06570, Ankara, Maltepe, Turkey
248 Hacettepe University School of Medicine, Turkey
249 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...